LEHVOSS Nutrition’s Game-Changing Joint and Cartilage Support Formulation With Univestin® + AmLexin™
TACOMA, WASHINGTON – July 07, 2025: Unigen Inc., a natural product R&D and proprietary company, is excited to collaborate with LEHVOSS Nutrition on their promotional launch of Univestin® + AmLexin™ joint and cartilage support for the EU Joint Health market.
The combination of Univestin® + AmLexin™ was recently featured in Nutraceutical Business Review under Unigen’s brand name ArthroLexin™. It is commercially sold under that name in USA and other markets with the exception of Europe, where Unigen’s distributor LEHVOSS Nutrition sells it as Univestin® + AmLexin™ combination at the moment.
Univestin® is a novel plant-based joint-care ingredient containing proprietary bioflavinoids derived from the roots of Scutellaria baicalensis and heartwood of Acacia catechu. Univestin® is clinically proven to promote joint flexibility within 3 days, support joint comfort within 5 days and support range of motion and physical function within 7 days.
AmLexin™ is a natural joint-care ingredient derived from the root bark of Morus alba and heartwood of Acacia catechu. AmLexin™ is clinically proven to help protect joints from natural wear and tear and demonstrated statistically significant reduction of uCTX-II, a type II collagen biomarker of joint cartilage break down.
Clinical research highlights the synergistic benefits of Univestin® and AmLexin™ in a unique formulation for joint and cartilage support, healthy aging, and overall joint health. By working effectively together, Univestin® combined with AmLexin™ help reduce joint discomfort, enhance flexibility and support the preservation of the articular cartilage matrix integrity composition.
“Unigen is a leading natural product research institute,” explained Dr. Qi Jia, Chief Scientific Officer, Unigen, Inc. “We have introduced two generations of joint care ingredients separately as Univestin® and AmLexin™ from mechanism-of-action-based screening through our PhytoLogix library of medicinal plants.” Univestin® is the first generation of joint care ingredients patented by Unigen targeting fast and long-lasting symptom relief. AmLexin™ is a symptom modifying natural active protecting cartilage from wear and tear and slowing down the catabolic process.”
“The powerful, synergistic combination of Univestin® with AmLexin™ not only contributes symptom relief, but also provides joint cartilage structural protection,” said Dr. Jia. “We strongly believe the development of nutraceutical compositions, like Univestin® + AmLexin™, should be scientific-evidence based and clinically proven. We hope this joint care research demonstrates the pathways and how the chain of scientific evidence is collected when our peers consider developing unique formulas for the nutraceutical industry.”
“The results of this combination study and individual studies on both ingredients confirm that Univestin® and AmLexin™ are certainly an alternative, innovative, plant-based solution for the European market, not only for OA management, but also for joint health and active’s lifestyle support,” added Teresita Rudà, Head of Marketing and Brand Positioning at LEHVOSS Nutrition.
For more information on this game-changing formulation for joint health in the EU, contact LEHVOSS.
REFERENCES
Yimam M et al. (2017) Cartilage Protection and Analgesic Activity of a Botanical Composition Comprised of Morus alba, Scutellaria baicalensis, and Acacia catechu, Evid Based Complement Alternat Med. 2017 Aug 20;2017:7059068. doi: 10.1155/2017/7059068
Sampalis J., L.A. Brownell. 2012. A randomized, double blind, placebo and active comparator controlled pilot study of UP446, a novel dual pathway inhibitor anti-inflammatory agent of botanical origin. Nutrition Journal. 11(21). doi:10.1186/1475-2891-11-21.
Kalman DS, Hewlings SJ. The Effects of Morus alba and Acacia catechu on Quality of Life and Overall Function in Adults with Osteoarthritis of the Knee. J Nutr Metab. 2017; 2017:4893104. doi: 10.1155/2017/4893104. Epub 2017 Sep 11. PMID: 29085676; PMCID: PMC5612321.
###
Kathy Markham
Marketing Manager, Unigen, Inc.
Email: kmarkham@unigen.net
Website: unigen.net
Teresita Rudà
Head of Marketing and Brand Positioning LEHVOSS Nutrition
+39 345 842 1899
Email: teresita.ruda@LEHVOSS.co.uk
Website: www.LEHVOSS-nutrition.com
About Unigen, Inc.
Unigen discovers, develops, and manufactures proprietary natural-product active ingredients for dietary supplements, cosmetic and personal care products, prescription medical food and botanical drug products. The Company discovers its ingredients through its high-throughput screening PhytoLogix® approach applied to a proprietary well-annotated collection of botanicals and a legacy mining approach applied to botanicals having known medicinal benefits.
Mechanism of action, safety, and efficacy are documented with extensive preclinical in vitro and by human clinical studies. Unigen protects its discoveries with issued patents and patent filings in all major territories and manufactures its products to GMP standards. Unigen commercializes its proprietary ingredients through licensing and ingredient supply alliances with commercial partners engaged in the manufacture, distribution, and marketing of end-products in each of Unigen’s target markets.
ABOUT LEHVOSS NUTRITION
LEHVOSS Nutrition is a business activity of the LEHVOSS Group, dedicated to the marketing and distribution of nutraceutical ingredients and minerals for Food Supplements, Functional Foods and Animal Health applications. We specialize in scientifically proven and added-value ingredients manufactured by top worldwide companies and distributed by our LEHVOSS subsidiaries throughout Europe. LEHVOSS group headquarters is based in Hamburg.